Park Medi World Limited has issued a strategic update regarding its ongoing acquisition of the KP Institute of Medical Sciences (KPIMS) in Agra. Following the successful 100% stake acquisition of KPS Wellness Private Limited in January, the company has now extended the indicative timeline for completing the acquisition of the remaining target entity, SVPD Healthcare Private Limited. This final phase of the transition is now expected to be finalized by March 31, 2026.

The notice serves as a formal disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The core of the update involves the 360-bed KP Institute of Medical Sciences, which Park Medi World is bringing under its umbrella by acquiring 100% shareholding in two specific entities: KPS Wellness Private Limited and SVPD Healthcare Private Limited. While the KPS Wellness portion is already complete, the company cited a mutual understanding for the adjusted March 31 deadline regarding SVPD Healthcare. All other terms and details of the original December 2025 acquisition agreement remain unchanged.

Park Medi World Limited, formerly known as Park Medi World Private Limited, is a significant player in the North Indian healthcare sector, operating under the well-known “Park Hospital” brand. The company focuses on multi-specialty healthcare services, providing advanced medical care across various disciplines including cardiology, oncology, and neurology. Throughout 2025, the company aggressively pursued an expansion strategy to increase its bed capacity and geographical footprint in the Delhi-NCR and Haryana regions. The acquisition of KPIMS in Agra marks a critical step in its mission to provide tertiary care in Tier-2 cities, strengthening its presence beyond the immediate capital region.

Regarding financial performance, the company has shown a steady trajectory in its recent 2025 filings. For the quarter ending September 30, 2025, Park Medi World reported a consolidated revenue of ₹215 Crores, representing a 12% growth compared to the previous year. Net profit for the same period stood at ₹18.5 Crores, reflecting improved operational margins across its hospital chain. The company’s growth has attracted attention from notable institutional investors, with specialized healthcare funds maintaining a steady stake. During 2025, the company also focused on upgrading its diagnostic infrastructure, which has been a primary driver for the increase in outpatient department (OPD) revenue.